The condition of prostate cancer persists as a global healthcare issue that requires better diagnostic methods that can be both accurate and accessible and invasive-free in nature. The adoption of biosensors for early disease detection and monitoring remains restricted because of multiple existing technological, biological, and systemic challenges. This chapter provides a thorough assessment of different challenges that prevent prostate cancer biosensors from moving from research environments into standard medical practice. The analytical approach identifies three main detection barriers from signal noise, minimal instrument size, and two biological challenges that affect test accuracy. Such data security problems, along with algorithmic bias and limited resource access within poor contexts, demonstrate why sustainable and inclusive technologies should be created, which leads to the necessary ethical and legal framework development. Medical facilities should first tackle integration issues between clinical systems and decision support solutions before implementing artificial intelligence interpretation approaches, which both preserve performance quality and build trusted procedures. The chapter provides strategic planning for the creation of multimodal intelligent biosensor systems, which can execute real-time monitoring and individual risk assessment. The research develops a comprehensive perspective about prostate cancer diagnostics by connecting information from technology with biology and clinical reality while addressing ethical considerations to create better clinical applications for oncology.